Insider Sales Weigh on Pulse Biosciences Amid Promising nPulse Data

Key points at a glance
- Close (yesterday): $22.92, down 9.2%
- Insider activity: Chief Commercial Officer Kevin Patrick Danahy sold 40,000 shares
- Clinical data: Strong results for the nPulse system in AF treatment
- Next catalyst: Q4 and full-year 2025 results due after the close on February 19, 2026

Insider activity details
Regulatory filings show Kevin Patrick Danahy, Pulse?s Chief Commercial Officer, divested a total of 40,000 shares in two rounds. The first tranche, 20,000 shares, was sold on February 9 at an average price of $21.45 per share; the second tranche, another 20,000 shares, followed on February 11 at $25.20 per share. Both sales were conducted under a Rule 10b5-1 plan that had been established in May 2025, a framework designed to allow insiders to schedule trades in advance to avoid concerns about trading on non-public information. Despite the orderly setup, traders reacted to the reduced float after the prior price advance, contributing to yesterday?s price decline.

Positive trial data amid volatility
The stock?s downside came as the company had recently traded higher on highly favorable clinical findings for its nPulse system. At a Boston-area symposium in early February, Pulse showcased data from a feasibility study evaluating the nPulse-based catheter for atrial fibrillation management. Among the 75 patients assessed, procedures reached a 100% success rate after six months.

Longer-term outcomes remained robust: among the 47 patients who reached the 12-month follow-up, the success rate stood at 96%. The safety profile also appeared favorable, with a rate of serious adverse events at just 1.3%.

Should investors sell immediately? Or is it worth buying Pulse Biosciences?

Upcoming quarterly figures and catalysts
With clinical results and insider activity now in the rearview, investors are turning their attention to Pulse Biosciences? financial performance. The company is scheduled to report fourth-quarter and full-year 2025 results on Thursday, February 19, 2026, after the market closes.

Key topics expected in the release include updates to the commercialization strategy for the nPulse system. Another focal point will be progress on the NANOPULSE AF study, for which a FDA IDE has been in place since December 2025.

Ad

Pulse Biosciences Stock: New Analysis - 13 February

Fresh Pulse Biosciences information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Pulse Biosciences analysis...